研究单位：[1]Huashan Hospital[2]The First Affiliated Hospital of Anhui Medical University[3]Anhui Provincial Hospital[4]Beijing YouAn Hospital[5]Peking University People's Hospital[6]Peking University First Hospital[7]Xiamen Hospital of Traditional Chinese Medicine[8]First Affiliated Hospital of Fujian Medical University[9]LanZhou University[10]Third Affiliated Hospital, Sun Yat-Sen University[11]First Affiliated Hospital of Guangxi Medical University[12]The Affiliated Hospital Of Guizhou Medical University[13]Hainan General Hospital[14]Hebei Medical University Third Hospital[15]The First Affiliated Hospital of Henan University of Traditional Chinese Medicine[16]Henan Provincial People's Hospital[17]The Second Affiliated Hospital of Harbin Medical University[18]Tongji Hospital[19]Wuhan Union Hospital, China[20]Renmin Hospital of Wuhan University[21]Central South University[22]Xiangya Hospital of Central South University[23]The First Hospital of Jilin University[24]the Second Hospital of Nangjing[25]The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School[26]The First Affiliated Hospital with Nanjing Medical University[27]The Affiliated Hospital of Xuzhou Medical University[28]The First Affiliated Hospital of Nanchang University[29]Shengjing Hospital[30]Qingdao Sixth People's Hospital[31]Shandong Provincial Hospital Affiliated to Shandong First Medical University[32]The Second Hospital of Shandong University[33]The First Affiliated Hospital of Shanxi Medical University[34]Tang-Du Hospital[35]First Affiliated Hospital Xi'an Jiaotong University[36]Ruijin Hospital[37]West China Hospital[38]Tianjin Second People's Hospital[39]First Affiliated Hospital of Xinjiang Medical University[40]The First People's Hospital of Yunnan[41]Shulan (Hangzhou) Hospital[42]Zhejiang University[43]Southwest Hospital, China[44]The Second Affiliated Hospital of Chongqing Medical University[45]Sichuan Provincial People's Hospital[46]Anhui Provincial Hospital,Hefei,Anhui,China,230000[47]The First Affiliated Hospital of Anhui Medical University,Hefei,Anhui,China,230000[48]Beijing YouAn Hospita,Beijing,Beijing,China,100000[49]Peking University First Hospital,Beijing,Beijing,China,100000[50]Peking University People's Hospital,Beijing,Beijing,China,100000[51]The Second Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China,400000[52]the Southwest Hospital of AMU,Chongqing,Chongqing,China,400000[53]First Affiliated Hospital of Fujian Medical University,Fuzhou,Fujian,China,350000[54]Xiamen Hospital of Traditional Chinese Medicine,Xiamen,Fujian,China,361000[55]the First Hospital of Lanzhou University,Lanzhou,Gansu,China,730000[56]First Affiliated Hospital of Guangxi Medical University,Nanning,Guangxi,China,530000[57]The Affiliated Hospital Of Guizhou Medical University,Guiyang,Guizhou,China,55000[58]The Second Affiliated Hospital of Harbin Medical University,Ha'erbin,Ha'erbin,China,150000[59]Hainan General Hospital,Haikou,Hainan,China,570100[60]the Third Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,050000[61]Henan Provincial People's Hospital,Zhengzhou,Henan,China,450000[62]The First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou,Henan,China,450000[63]Renmin Hospital of Wuhan University,Wuhan,Hubei,China,430000[64]Tongji Hospital,Wuhan,Hubei,China,430000[65]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430000[66]the Second Xiangya Hospital of Central South University,Changsha,Hunan,China,430100[67]Xiangya Hospital Central South University,Changsha,Hunan,China,430100[68]Jiangsu Province Hospital,Nanjing,Jiangsu,China,210000[69]The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,Nanjing,Jiangsu,China,210000
研究目的：
The goal of this multicenter, observational, prospective study is to observe and compare different anti-viral treatment strategies in a real-world cohort of patients with CHB managed in routine clinical settings in China. The main questions it aims to answer are: 1. To evaluate the benefits of initiating first-line nucleos(t)ide analogue in patients with chronic HBV infection who are recommended in the updated Chinese Guideline 2022, but not recommended in the Chinese Guideline 2019. 2. To evaluate the Chinese Guideline recommends initiation of treatment, but at least one foreign authoritative guideline (eg. AASLD, EASL) does not recommend the benefit of initiating first-line nucleos(t)ide analogue in patients with chronic HBV infection who initiate treatment. 3. To compare the treatment effect of different alternatives with patients who have partial response after treatment with first-line nucleos(t)ide analogues.
